Metastatic castration-resistant prostate cancer
1 paper
- Humans1
Trial sponsors
Company4 trialsPhase 32,535 people
Company1 trialPhase 1/2277 people
Company1 trialPhase 1174 people
Company1 trialPhase 136 people
Company1 trialPhase 116 people
Allife Medical Science and Technology
Company1 trialEarly phase 19 people
Nanjing NingQi Medicine Science and Technology
Company1 trialEarly phase 19 people
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3 trialsPhase 2125 people
Latest
2 in 12 monthsWorld Journal of Urology
Frailty and comorbidity surpass probable sarcopenia in predicting survival of mCRPC patients treated with first-line ARPIs: a comprehensive geriatric analysis
Cohort study of 213 peopleSarcopenia